decaux - Search Results - UAB Digital Repository of Documents

Search collections:

Sort by:	Display results:	Output format:

Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found

Articles	1 records found

8 p, 2.0 MB

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial / Bahlis, Nizar J (University of Calgary) ; Corso, A. (Policlinico San Matteo Universita di Pavia) ; Mugge, L.O. (Universitätsklinikum Jena Klinik für Innere Medizin II) ; Shen, Z.X. (Shanghai Jiao Tong University) ; Desjardins, Pierre (Hôpital Charles LeMoyne) ; Stoppa, A.M. (Institut Paoli Calmettes) ; Decaux, O. (CHRU Hôpital Sud Médecine Interne) ; De Revel, T. (Hôpital d'Instruction des Armées PERCY) ; Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Marit, G. (CHU de Bordeaux) ; Nahi, H. (Karolinska Institutet (Suecia)) ; Demuynck, H. (H. Hart Ziekenhuis Roeselare-Menen) ; Huang, S.Y. (National Taiwan University Hospital (Taipei, Taiwan)) ; Basu, S. (New Cross Hospital) ; Guthrie, T.H. (21st Century Oncology) ; Ervin-Haynes, A. (Celgene Corporation) ; Marek, J. (Celgene Corporation) ; Chen, G. (Celgene Corporation) ; Facon, T. (CHRU Lille) ; Universitat Autònoma de Barcelona
The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thalidomide for 12 cycles (MPT) and Rd for 18 cycles (Rd18) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) showed that Rd continuous prolonged progression-free survival and overall survival compared with MPT. [...]
2017 - DOI (Digital Object Identifier)

10.1038/leu.2017.111
Leukemia, Vol. 31 Núm. 11 (january 2017) , p. 2435-2442

Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.